Immunother Limited to study stomach enzymes which could cure intestinal diseases
Immunother Limited today announced that they have been studying enzymes to break down mucus in the stomach could provide analysis for intestinal diseases.
By: Immunother Limited
Immunother Limited's research offers a significant step forward in the understanding of complex stomach muscles and our researchers anticipate it can be used in the development of new treatment for intestinal diseases.
Immunother Limited's Chairman & Chief Scientist, Mr. Geoffrey Marcus PhD commented on the clinical enzymes study saying "Our team has researched how this enzyme sits on the outside of the bacterial cell and eats away parts of the mucin molecule, taking them inside the bacterial cell to be consumed. The human body constantly produces a thin layer of mucus in the stomach that provides a barrier."
"Mucin or mucus contain sugar molecules called glycans, and these also provide an essential source of nutrients for bacteria to feed on. What we have found is that glycans are known to change when certain diseases are present in the human body, and our medical team of researchers anticipate it will be possible to use the stomach enzymes to analyze the glycans by doing a biopsy for early detection of the disease," added Geoffrey Marcus, Chairman & Chief Scientist of Immunother Limited.
About Us - Immunother Limited
Immunother Limited Company is a privately held Shenzhen-based preclinical stage biotechnology company focused on discovering and developing novel therapies for inflammatory diseases.
Immunother Limited Company creates lasting value through pioneering research in the field of immunology which leads to new product concepts, product development, and finally to the licensing of those products and associated intellectual property.